Trial report in Antimicrobial agents and chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors.
Neta PetersielVictorian Infectious Diseases Service, The Royal Melbourne Hospital, The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.ORCID 0000-0003-1981-3848
Stefano GiulieriVictorian Infectious Diseases Service, The Royal Melbourne Hospital, The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.ORCID 0000-0001-5366-1943
Diane S DanielDepartment of Microbiology and Immunology, The University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Sook-Ha FanThe Lundquist Institute for Biomedical Innovation, Torrance, California, USA.
Selvi C ErsoyThe Lundquist Institute for Biomedical Innovation, Torrance, California, USA.ORCID 0000-0002-8792-2061
Joshua S DavisMenzies School of Health Research and Charles Darwin University, Darwin, Northern Territory, Australia.ORCID 0000-0001-9864-5699
Arnold S BayerThe Lundquist Institute for Biomedical Innovation, Torrance, California, USA.
Benjamin P HowdenDepartment of Microbiology and Immunology, The University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
Steven Y C TongVictorian Infectious Diseases Service, The Royal Melbourne Hospital, The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.ORCID 0000-0002-1368-8356
CAMERA2 study group
Funding
Bicarbonate-Mediated Enhancement of Beta-Lactam-MRSA Killing: Mechanisms and Clinical TranslatabilityR01AI146078 · NIAID · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI XIONG, YAN Q. · 2019 to 2023
$1.9M
DHAC | National Health and Medical Research Council (NHMRC) 1078930HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) 1RO1AI146078MOH | National Medical Research Council (NMRC) 0001-001094NIAID NIH HHS R01 AI146078
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Genomic investigation and clinical correlates of the · full record | OpenQuestion